Clinical trials: Intestinal Dysplasia
Enterocolitis, Necrotizing, Bacteremia
Antibiotic "Dysbiosis" in Preterm Infants
Prolonged antibiotic use in preterm neonates has significant consequences on the developing intestinal microbiome, metabolome and host response, predisposing the neonate to various major morbidities, including necrotizing…
- Conditions
- Enterocolitis, Necrotizing, Bacteremia, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage
- Trial name
- NCT02784821
- Testing
- Antibiotic, Gastric fluid, Breast milk
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- University of Florida
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01789255
- Testing
- vorinostat, tacrolimus, cyclosporine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Colon Carcinoma, Dysplasia in Crohn Disease
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
This pilot, randomized phase I/II trial studies how well inositol works in preventing colorectal cancer in patients with abnormal cells (dysplasia) associated with inflammation of the colon (colitis).
- Conditions
- Colon Carcinoma, Dysplasia in Crohn Disease, Low Grade Dysplasia in Ulcerative Colitis, Rectal Carcinoma
- Trial name
- NCT01111292
- Testing
- Inositol
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Barrett Esophagus
Ablation of Intestinal Metaplasia Containing Dysplasia
The purpose of this study is to determine if the intervention of a 510(k)-cleared endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is better than anti-secretory therapy alone in clearing…
- Trial name
- NCT00282672
- Testing
- Ablation System plus anti-secretory medication
- Where
- 19 sites in United States
- Volunteers
- 127 people
- Sponsor
- Medtronic - MITG
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women.
- Trial name
- NCT01034358
- Testing
- Human Papillomavirus Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Anus Neoplasms
Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream
The purpose of this study is to find out if a Chinese herbal cream is effective in treating HSIL (high-grade squamous intraepithelial lesions, also known as HGAIN, or high-grade anal intraepithelial neoplasia).
- Trial name
- AIJP (NCT00622440)
- Testing
- AIJP (Arnebia Indigo Jade Pearl)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Colorectal Adenoma, Colorectal Carcinoma
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps).
- Conditions
- Colorectal Adenoma, Colorectal Carcinoma, Colorectal Conventional Adenoma With Severe Dysplasia, Colorectal Tubulovillous Adenoma
- Trial name
- NCT02134925
- Testing
- Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Barrett Esophagus
HALO Patient Registry: Ablation of Barrett's Esophagus
The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD).
- Trial name
- NCT00848237
- Testing
- Radiofrequency Ablation (HALO Ablation Systems)
- Where
- United States
- Volunteers
- 5,521 people
- Sponsor
- Medtronic - MITG